Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827776 | 0.89 | C5AR1 (0.47) | C5AR1OPRM1P2RX7DPP4CHRM1 | |
| SCHEMBL9983080 | 0.86 | C5AR1 (0.43) | C5AR1OPRM1P2RX7DPP4ALDH1A1 | |
| SCHEMBL9982661 | 0.83 | C5AR1 (0.41) | C5AR1OPRM1P2RX7DPP4MAPT | |
| SCHEMBL9982494 | 0.77 | OPRM1 (0.40) | C5AR1OPRM1DPP4ALDH1A1CYP3A4 | |
| SCHEMBL9982680 | 0.76 | C5AR1 (0.49) | C5AR1OPRM1MITFMAPTKMT2A | |
| SCHEMBL9982482 | 0.74 | OPRM1 (0.48) | C5AR1OPRM1ALDH1A1CHRM1 | |
| SCHEMBL12069839 | 0.74 | OPRM1 (0.43) | C5AR1OPRM1P2RX7MAPTKMT2A | |
| SCHEMBL14826279 | 0.74 | TNF (0.37) | C5AR1P2RX7DPP4MAPTALDH1A1 | |
| SCHEMBL12067697 | 0.73 | C5AR1 (0.41) | C5AR1OPRM1P2RX7MAPTALDH1A1 | |
| SCHEMBL9982783 | 0.73 | MAPT (0.45) | C5AR1OPRM1MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582681-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | C5AR1 1212/4885OPRM1 956/4885P2RX7 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.